文献速递消化系统肿瘤

8基因特征联合黏液成分分层预测dMMR/MSI-H转移性结直肠癌双免疫联合获益

From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer.
PubMed 文献 · Eur J Cancer · 2026-04-05

研究基于两个独立队列的预处理样本3'RNA测序数据,训练并验证了k-TSP分类器以预测转录组Cluster A,并结合黏液成分构建复合分层。在163例患者中,Cluster A且含黏液成分者占15.3%,接受抗PD-1+抗CTLA-4较单药显著改善24个月PFS(72.2% vs 13.8%,HR 0.10,95%CI 0.02-0.39,p<0.001)。

要点

  • 8基因k-TSP分类器可预测Cluster A,验证队列平衡准确率68.1%。
  • Cluster A富含黏液性肿瘤且两队列中PFS更短。
  • Cluster A+黏液成分者从双免疫联合中显著获益。

核心结论

  • 8基因特征联合黏液成分可识别优先从抗PD-1+抗CTLA-4联合治疗中获益的dMMR/MSI-H mCRC亚组。
  • 该复合分层与治疗交互作用改善模型拟合(似然比p≈0.04)。

研究设计与样本

  • 使用两个独立队列预处理样本的3'RNA测序数据,Cohort 1(103例)训练,Cohort 2(87例)验证。
  • 患者接受抗PD-1±抗LAG-3(Mono)或抗PD-1+抗CTLA-4(Combo)治疗,排除接受抗PD-L1及ECOG≥2者。

主要发现

  • k-TSP选出四对基因预测Cluster A:YPEL2>H2AZ1、H6PD>COX7A2、STAT5B>SNRPE、ZHX3>TRAPPC4。
  • Cohort 2验证平衡准确率68.1%。
  • Cluster A富含黏液性肿瘤且两队列PFS更短。
  • 合并人群(163例)中Clusterk-TSP A+黏液者25/163(15.3%),Combo vs Mono调整24个月PFS 72.2% vs 13.8%(HR 0.10,95%CI 0.02-0.39;p<0.001)。

关键数值与推荐

  • 复合分层交叉Clusterk-TSP(A vs B/C)与黏液成分(存在 vs 缺失)。
  • Clusterk-TSP A+黏液定义为优先获益亚组。

临床怎么用

  • 可考虑用8基因特征联合黏液成分分层指导dMMR/MSI-H mCRC一线免疫方案选择。
  • Clusterk-TSP A+黏液患者可能优先选择抗PD-1+抗CTLA-4联合而非单药。

局限性

  • 需前瞻性验证以指导临床决策。
  • 研究基于回顾性队列数据,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Around 15-50% of patients with dMMR/MSI-H metastatic colorectal cancer (mCRC) experience primary and secondary resistance to immune checkpoint inhibitors (ICI). We previously described three transcriptomic clusters (A, B, C) linked to progression-free survival (PFS), with cluster A ("StromalHIGH - ProliferationLOW") associated with the shortest PFS. Here we combine gene signature and mucinous phenotype to predict the benefit from anti-CTLA-4 plus anti-PD-1. METHODS: We used 3'RNA-sequencing data from pre-treatment samples of two independent cohorts of patients with dMMR/MSI-H mCRC treated with anti-PD-1 ±anti-LAG-3 ("Mono") or anti-PD-1 +anti-CTLA-4 ("Combo"). A rank-based k-Top Scoring Pairs (k-TSP) classifier was trained in Cohort 1 (103 patients) to predict assignment to Cluster A versus B/C and validated in Cohort 2 (87 patients). Patients receiving an anti-PD-L1 and with ECOG ≥ 2 were excluded. We defined a composite stratum crossing Clusterk-TSP (A vs B/C) with mucinous component (present vs absent). RESULTS: Cluster A was enriched for mucinous tumors and had shorter PFS in both cohorts. The k-TSP selected four gene pairs predictive of Cluster A (YPEL2 >H2AZ1, H6PD>COX7A2, STAT5B>SNRPE, ZHX3 >TRAPPC4) and was validated in Cohort 2 with 68.1% balanced accuracy. In the pooled population (163 patients), the composite stratum × treatment interaction improved model fit (likelihood-ratio p ≈ 0.04). Patients with Clusterk-TSP A + mucinous (25/163, 15.3%) derived advantage from Combo versus Mono: adjusted 24-month PFS 72.2% vs 13.8% (HR 0.10, 95% CI 0.02-0.39; p < 0.001). CONCLUSIONS: An 8-Gene signature combined with mucinous component identifies a subgroup that preferentially benefits from anti-PD-1 +CTLA-4, warranting prospective validation to guide regimen selection in dMMR/MSI-H mCRC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ambrosini M, Gallois C, Gandini A, et al. From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer. Eur J Cancer. 2026. PMID: 41950572. doi:10.1016/j.ejca.2026.116731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。